Arbutus Biopharma Corporation
ABUS
$5.15
-$0.03-0.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -99.43% | 16,943.39% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -99.43% | 16,943.39% | |||
| Cost of Revenue | -29.66% | -17.70% | |||
| Gross Profit | -101.08% | 4,524.93% | |||
| SG&A Expenses | -34.34% | 59.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -32.41% | 15.11% | |||
| Operating Income | -103.40% | 2,312.41% | |||
| Income Before Tax | -103.03% | 4,617.97% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -103.03% | 4,617.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -103.03% | 4,617.97% | |||
| EBIT | -103.40% | 2,312.41% | |||
| EBITDA | -103.39% | 2,315.75% | |||
| EPS Basic | -102.97% | 4,591.28% | |||
| Normalized Basic EPS | -102.85% | 2,590.91% | |||
| EPS Diluted | -103.45% | 4,561.54% | |||
| Normalized Diluted EPS | -102.87% | 2,572.73% | |||
| Average Basic Shares Outstanding | 1.91% | 0.74% | |||
| Average Diluted Shares Outstanding | 1.16% | 1.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||